Twirla Patch
Product Images NDC 71671-100

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Twirla (NDC 71671-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Agile Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Fig2a

Fig2a
This is a list of studies that compare the use of combined oral contraceptive (COC) and the risk of certain outcomes. The studies examine different populations and use different measures of effect, such as odds ratios (OR), relative risks (RR), and hazard ratios (HR). The outcomes studied are not specified in the given text.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This appears to be a medical chart that displays information about a certain group of non-pregnant women who are CHC Users. It also provides information about pregnancy and postpartum. The chart includes ranges for several different variables such as 1105 and 3012. There is also a graph that shows the number of women with a blood clot out of 10,000 Woman-Years (W).*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
Lovonorgestrel is a chemical compound with molecular formula CaiH2:02 and molecular weight 312.45. Pyl Estradial is another chemical compound with molecular formula CaoHzO2 and molecular weight 296.41. These compounds may be used in medical and pharmaceutical applications, but further context is needed to determine their specific uses.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
This is a description of a woven peripheral backing layer for use in medical applications. The layer has an inactive peripheral acrylic adhesive layer and an inactive peripheral polyisobutylene adhesive layer. The layer also features an internal membrane and an active adhesive matrix. To prevent sticking, a polyester release liner is included.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
FDA Label Image

No-placement (No Placement)

No-placement (No Placement)
FDA Label Image

Placement (Placement)

Placement (Placement)
FDA Label Image

Image Description (Twirla Application 0)

Image Description (Twirla Application 0)
FDA Label Image

Image Description (Twirla Application 1)

Image Description (Twirla Application 1)
FDA Label Image

Image Description (Twirla Application 10)

Image Description (Twirla Application 10)
FDA Label Image

Image Description (Twirla Application 2)

Image Description (Twirla Application 2)
FDA Label Image

Image Description (Twirla Application 4)

Image Description (Twirla Application 4)
FDA Label Image

Image Description (Twirla Application 5)

Image Description (Twirla Application 5)
FDA Label Image

Image Description (Twirla Application 6)

Image Description (Twirla Application 6)
FDA Label Image

Image Description (Twirla Application 6a)

Image Description (Twirla Application 6a)
FDA Label Image

Image Description (Twirla Application 7)

Image Description (Twirla Application 7)
FDA Label Image

Image Description (Twirla Application 8)

Image Description (Twirla Application 8)
FDA Label Image

Image Description (Twirla Application 9)

Image Description (Twirla Application 9)
FDA Label Image

Twirla-carton-1-replacement (Twirla Carton 1 Replacement)

Twirla-carton-1-replacement (Twirla Carton 1 Replacement)
Twirla is a contraceptive patch containing norgestrel and ethinyl estradiol. It is designed to prevent pregnancy but does not protect against sexually transmitted diseases or HIV/AIDS. The package contains one replacement transdermal system intended for transdermal use only. The instructions on how to use the patch can be found on the prescribing information included inside the package.*
FDA Label Image

Image Description (Twirla Carton 3 Trade)

Image Description (Twirla Carton 3 Trade)
Description: This is a package of medication containing a contraceptive patch containing a combination of levonorgestrel and ethinyl estradiol. It is recommended for transdermal use only to prevent pregnancy and protect against sexually transmitted infections. The package contains 2 patches and its contents include a transdermal system. Recommended dosages are provided along with the components of the medication. The text includes details such as temperature and storage guidelines.*
FDA Label Image

Image Description (Twirla Pouch)

Image Description (Twirla Pouch)
This is a description of a contraceptive transdermal patch that contains levonorgestel and efiny esiraiol. The patch is intended to prevent pregnancy but does not protect against sexually transmitted diseases. The recommended dosage is to apply the patch immediately upon its removal from the pouch and wear it for seven days before discarding it. The product should be stored at room temperature. It is not recommended to flush used transdermal systems down the toilet.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.